Compare HLN & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLN | MIST |
|---|---|---|
| Founded | 2022 | 2003 |
| Country | United Kingdom | Canada |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.8B | 131.3M |
| IPO Year | 2021 | 2019 |
| Metric | HLN | MIST |
|---|---|---|
| Price | $10.18 | $1.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 10.3M | 1.7M |
| Earning Date | 02-26-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.94% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.55 | $2,915.14 |
| Revenue Next Year | $4.42 | N/A |
| P/E Ratio | $49.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.65 | $1.00 |
| 52 Week High | $11.28 | $3.06 |
| Indicator | HLN | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 57.68 | 43.93 |
| Support Level | $9.61 | $1.01 |
| Resistance Level | $10.23 | $1.42 |
| Average True Range (ATR) | 0.13 | 0.07 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 79.69 | 22.22 |
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.